Proteomedix Earlier Announced Agreement To Issue Labcorp Exclusive License For Proclarix Blood Test To Detect Prostate Cancer
Portfolio Pulse from Charles Gross
Proteomedix has granted Labcorp an exclusive license to develop and commercialize the Proclarix blood test for prostate cancer detection in the U.S. The test offers a non-invasive alternative to prostate biopsies in appropriate cases.
May 22, 2023 | 8:55 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Labcorp has been granted an exclusive license by Proteomedix to develop and commercialize the Proclarix blood test for prostate cancer detection in the U.S.
Labcorp has been granted an exclusive license to develop and commercialize the Proclarix blood test in the U.S., which could potentially increase their market share in the diagnostics sector. This partnership with Proteomedix is likely to have a positive impact on Labcorp's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100